<DOC>
	<DOCNO>NCT02910505</DOCNO>
	<brief_summary>Single center study evaluate safety efficacy investigational version Cutera enlightenTM laser offer multiple wavelength tattoo removal .</brief_summary>
	<brief_title>A Study Novel Multi-Wavelength Laser Tattoo Removal</brief_title>
	<detailed_description>A single-center prospective , open-label , uncontrolled pilot study evaluate safety efficacy investigational version Cutera enlightenTM laser offer multiple wavelength tattoo removal .</detailed_description>
	<criteria>Female Male , 18 65 year age ( inclusive ) . Fitzpatrick Skin Type I VI . Target tattoo contain single multicolor ink . Subject must able read , understand sign Informed Consent Form . Must willing able adhere treatment followup schedule posttreatment care instruction . Wiling cover tattoo bandage clothing ; and/or limited sun exposure use approve sunscreen SPF 50 high treat area start 2 4 week treatment and/or every day duration study , include followup period . Willing digital photograph take treatment area agree use photograph presentation , educational marketing purpose . Agree undergo procedure ( ) tattoo removal study ( applicable ) . Postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment entire course study , plan become pregnant duration study . Participation clinical trial drug another device target area study . Target tattoo contain black ink . History allergic reaction pigment follow tattooing . History allergy local anesthetic . History allergy topical antibiotic . History malignant tumor target area . Skin abnormalities target area , e.g. , cut , scrape , wound , scar , large mole . Pregnant and/or breastfeeding . Having infection , dermatitis rash treatment area . Significant concurrent illness , diabetes mellitus cardiovascular disease , e.g. , uncontrolled hypertension . Suffering coagulation disorder take prescription anticoagulation medication . History keloid scarring , hypertrophic scar abnormal wound healing . History immunosuppression/immune deficiency disorder currently use immunosuppressive medication . History vitiligo , eczema , psoriasis . History connective tissue disease , systemic lupus erythematosus scleroderma . History seizure disorder due light . Any use medication know increase sensitivity light accord Investigator 's discretion . History disease stimulate heat , recurrent herpes simplex and/or herpes zoster ( shingle ) treatment area , unless treatment conduct follow prophylactic regimen History radiation treatment area undergo systemic chemotherapy treatment cancer . History pigmentary disorder , particularly tendency hyper hypopigmentation . Systemic use corticosteroid isotretinoin within 6 month study participation . Anytime life , use gold therapy ( gold salt ) disorder rheumatologic disease lupus . Excessively tanned area treat unable/unlikely refrain tan study . Current smoker history smoking within 6 month study participation . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>